Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 15,616 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin and Connective Tissue Disease Clear all

Conditions: Melanoma (Skin)
Interventions: recombinant interferon alfa, lymphangiography, Observation; Biological · Procedure · Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 70 Years
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2007
U.S. locations: 4
States / cities: Birmingham, Alabama • Louisville, Kentucky • New Brunswick, New Jersey + 1 more

Conditions: Breast Cancer
Interventions: letrozole, DHEA, pharmacological study; Drug · Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 60 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Atopic Dermatitis (AD)
Interventions: Onabotulinum Toxin Type A - Phase 1b, Onabotulinum Toxin Type A - Phase 2; Drug
Lead sponsor: Daniel Kaplan; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Acne Vulgaris
Interventions: Clindamycin Phosphate, Clindamycin Phosphate RLD, Placebos; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer
Interventions: Trastuzumab Deruxtecan, Paclitaxel, Trastuzumab, Pertuzumab, Doxorubicin, cyclophosphamide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 927 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 22
States / cities: Springdale, Arkansas • Beverly Hills, California • Glendale, California + 19 more

Conditions: Breast Cancer
Interventions: CDX-011, "Investigator's Choice" chemotherapy; Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 24
States / cities: Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 19 more

Conditions: Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis
Interventions: Secukinumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 100 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 3
States / cities: Boise, Idaho • Cincinnati, Ohio • Portland, Oregon

Conditions: Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Melanoma
Interventions: Schirmer strip, a Class I Medical Device typically used to test for dry eye.; Other
Lead sponsor: Namida Lab; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Fayetteville, Arkansas

Conditions: Breast Cancer
Interventions: Self-Report Survey, Qualitative Interviews; Behavioral
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 25 Years to 85 Years · Female only
Enrollment: 265 participants
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Tampa, Florida

Conditions: Eczema
Interventions: Abrocitinib, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 13
States / cities: Birmingham, Alabama • North Little Rock, Arkansas • San Diego, California + 7 more

Conditions: Cutaneous Fistula
Interventions: Fistula Pouching System; Device
Lead sponsor: Coloplast A/S; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 7
States / cities: Hartford, Connecticut • Clearwarter, Florida • Edina, Minnesota + 3 more

Conditions: Rheumatoid Arthritis
Interventions: Repository corticotropin injection; Drug
Lead sponsor: Arthritis Treatment Center, Maryland; Other
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Frederick, Maryland

Conditions: Hand-foot Skin Reaction, Rash
Interventions: urea 40% cream, fluocinonide 0.05% cream, tazarotene 0.1% cream, bland emollient cream (Udderly smooth® Udder Cream); Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Systemic Lupus Erythematosus
Interventions: Anifrolumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Breast Neoplasms
Interventions: mHealth Intervention; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 21 Years and older · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Morquio Syndrome A, Maroteaux Lamy Syndrome, MPS IVA, MPS VI
Interventions: Not listed
Lead sponsor: Greenwood Genetic Center; Other
Eligibility: Up to 18 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Breast Cancer
Interventions: Cost Discussion; Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Breast Cancer
Interventions: bexarotene; Drug
Lead sponsor: Baylor Breast Care Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Houston, Texas • San Antonio, Texas

Conditions: Pyoderma Gangrenosum
Interventions: Deucravacitinib; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Breast Cancer
Interventions: isoflavones, carbohydrate; Dietary Supplement
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 30 Years to 42 Years · Female only
Enrollment: 197 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2023
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Actinic Keratoses
Interventions: PEP005 (ingenol mebutate) Gel, Vehicle gel; Drug
Lead sponsor: Peplin; Industry
Eligibility: 18 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 18
States / cities: Mesa, Arizona • Denver, Colorado • Kissimmee, Florida + 14 more

Conditions: Melanoma
Interventions: MELITAC 12.1 + Montanide ISA-51 + lipopolysaccharide (LPS), MELITAC 12.1 + Montanide ISA-51 + polyICLC; Biological
Lead sponsor: Craig L Slingluff, Jr; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Kidney Cancer, Melanoma (Skin)
Interventions: aldesleukin, recombinant interferon alfa; Biological
Lead sponsor: Hoag Memorial Hospital Presbyterian; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2000
U.S. locations: 4
States / cities: Newport Beach, California • Bloomington, Indiana • Knoxville, Tennessee + 1 more

Conditions: Malignant Melanoma
Interventions: ACY-241, nivolumab, ipilimumab; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis

Dehydroepiandrosterone (DHEA) and Letrozole in Treating Patients With Metastatic Breast Cancer

The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis

Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer

An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)

Investigating the Diagnostic Potential of Tear Proteins in Cancer - A Pilot Study

Barriers to Screening Breast MRI Utilization Among Patients at Elevated Risk

A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema

Feasibility Study of a New Fistula Pouching System

Repository Corticotropin Injection To Treat Rheumatoid Arthritis Patients Who Have Failed Three Biologic Therapies.

Sorafenib-induced Hand- Foot Skin Reaction Treatment

Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users

Mobile Health (mHealth) Black Women With Breast Cancer

Screening an Orthopedic Population for Mildly-affected Individuals With Morquio Syndrome A and Maroteaux-Lamy Syndrome

Understanding and Addressing Patient and Provider Preferences Around Discussions of Cost of Breast Cancer Care

Bexarotene in Preventing Breast Cancer in Women at Genetic Risk

Deucravacitinib in PG

Soy Isoflavones and Breast Cancer Risk Reduction

A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations

A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients

High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma

Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab